BLCO
BLCO
$16.61
+0.73% 2026-10-19
Sector n/a
BLCOSPY
1W
+3.4%
1M
-1.4%
3M
+3.9%
6M
-0.9%
YTD
-2.8%
1Y
+10.7%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap–
P/E (trailing)–
P/E (forward)–
52-week range– – –
Revenue growth (YoY, latest qtr)–
Dividend yield–
Analyst consensus–
Mean price target–
Valuation & fundamentals
Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -4 (DCF counts double).
▼DCF (base case)below the price by 124%
▼Piotroski F-score3/9
▼Net debt / EBITDA6.4x
Discounted cash flow
Bear
$-7
-145%
growth 6% · disc. 10.2% · term. 2.0%
Base
$-4
-124%
growth 11% · disc. 9.2% · term. 2.5%
Bull
$1
-96%
growth 14% · disc. 8.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Gross margin
–
Operating margin
6.1%
FCF margin
2.6%
Net margin
-3.2%
Return on equity
-2.7%
Return on invested capital
2.3%
Net debt / EBITDA
6.4×
Current ratio
1.5×
Interest cover
0.8×
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Analysts
No analyst targets available.
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $5.1B | $-360.0M | $-66.0M |
| 2024 | $4.8B | $-317.0M | $-59.0M |
| 2023 | $4.1B | $-260.0M | $-198.0M |
| 2022 | $3.8B | $6.0M | $170.0M |
| 2021 | $3.8B | $182.0M | $680.0M |
| 2020 | $3.4B | $-18.0M | $269.0M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +10.6%.
Earnings
Next report: 2026-10-28 · before open · EPS est 0.22
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | 0.16 | 0.16 | -0.3% |
| 2026-04-29 | 0.05 | 0.08 | +49.2% |
| 2026-02-18 | 0.36 | 0.32 | -10.3% |
| 2025-10-29 | 0.16 | 0.18 | +11.9% |
| 2025-07-30 | 0.08 | 0.07 | -16.9% |
| 2025-04-30 | 0.02 | -0.07 | -434.9% |
| 2025-02-19 | 0.23 | 0.25 | +6.9% |
| 2024-10-30 | 0.16 | 0.17 | +8.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.4B | +9.1% |
| 2026-03-31 | $1.2B | – |
| 2025-12-31 | $1.4B | – |
| 2025-09-30 | $1.3B | – |
| 2025-06-30 | $1.3B | – |
Insider trades
Munsch Frederick
$887.7K
SVP, Controller and CAO · 2026-08-10
SELL$887.7K
Von Eschenbach Andrew C.
$100.5K
Director · 2026-08-07
SELL$100.5K
Von Eschenbach Andrew C.
$206.2K
Director · 2026-08-06
SELL$206.2K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
StockStory · Oct 16
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
BioPharma Dive · Oct 12
Bausch + Lomb Names Thomas Appio Interim CEO; Expects to Raise 2026 Guidance
MT Newswires · Oct 12
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Business Wire · Oct 12
Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says
MT Newswires · Oct 08
3 Low-Volatility Stocks with Open Questions
StockStory · Oct 08
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
The Fly · Oct 07
Barclays Initiates Coverage on Bausch + Lomb With Overweight Rating, $24 Price Target
MT Newswires · Oct 07
Stats refreshed 2026-10-19 19:04:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau